Spyre Therapeutics (SYRE) reports fiscal Q4 2025 results with non-GAAP EPS -$0.70 (+14% YoY) and revenue $0, beating estimates, while highlighting $757M in cash providing runway into H2 2028 and confirming 2026 proof-of-concept readouts for its SKYLINE and SKYWAY Phase 2 trials
No comments:
Post a Comment
Note: Only a member of this blog may post a comment.